Clinical trials: Sickle Cell Disorder
Sickle Cell Disease, Diabetes Mellitus
Glucose Metabolism in Sickle Cell Disease
The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes.
- Trial name
- NCT02922296
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois Chicago
Sickle Cell Disease
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
Background: Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels.
- Trial name
- NCT06145282
- Testing
- Briquilimab, Filgrastim, Abatacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
A Study Aimed to Assess the Needs of Subjects With Sickle Cell Disease and Healthcare Professionals Managing Sickle Cell Disease Patients in Selected Nigerian Centres
This pilot research is aimed to assess the needs of patients and health workers involved in Sickle Cell Disease (SCD) management in Nigeria.
- Trial name
- NCT04505969
- Testing
- Questionnaire to assess needs
- Where
- 4 sites in Nigeria
- Volunteers
- 192 people
- Sponsor
- Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus
Sickle Cell Disease
Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
The purpose of this research study is to compare two different ways to give opioid pain medicine to treat sickle cell disease pain that is bad enough to go to the emergency department for treatment.
- Trial name
- COMPARE-VOE (NCT03933397)
- Testing
- Patient-Specific Protocol, Weight-based Protocol, Morphine
- Where
- 6 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Sickle Cell Disease
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials
- Trial name
- 034OLE (NCT03573882)
- Testing
- Voxelotor
- Where
- 60 sites in United States, Canada and 9 more
- Volunteers
- 179 people
- Sponsor
- Pfizer
Pain, Sickle Cell Disease
Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
The pathophysiology of sickle cell disease (SCD) manifestations, are complex with interactions of intracellular hemoglobin, membrane and endothelial activation but the hallmark remains recurrent and painful vaso-occlusive…
- Trial name
- COMPARE (NCT01380197)
- Testing
- Morphine, Nubain
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Healthcare of Atlanta
Sickle Cell Disease and G6PD Deficiency
Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency
G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist.
- Trial name
- NCT06615024
- Testing
- G6pd enzyme sickling test, G6PD enzyme and sickling test, G6PD enzyme and HPLC
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fatma Hussein Mahmoud
Stroke Ischemic, Sickle Cell Disease
Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease
DISPLACE is a three part, multi-center U.S. based study to evaluate the barriers to stroke screening and prevention in children with sickle cell anemia (SCA).
- Trial name
- DISPLACE (NCT03621826)
- Testing
- Questionnaire/Interview
- Where
- United States
- Volunteers
- 5,247 people
- Sponsor
- Medical University of South Carolina
Sickle Cell Disease
Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem…
- Trial name
- NCT06287099
- Testing
- BRL-101
- Volunteers
- 5 people
- Sponsor
- Bioray Laboratories
Sickle Cell Disease, Kidney Failure, Chronic
Kidney Function in Sickle Cell Anemia
This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in…
- Trial name
- NCT03277547
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Kenneth Ataga MD
Sickle Cell Disease
Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.
Sickle cell disease is a genetic disease responsible for an abnormal hemoglobin.The anomaly has several consequences: a low hemoglobin rate (chronic anemia), plugs formed by red blood cells in blood vessels (extremely painful…
- Trial name
- NCT02608580
- Testing
- Survey
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Brugmann University Hospital
Sickle Cell Disease
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in individuals with Sickle Cell Disease (SCD) who report…
- Trial name
- IMPROVE2 (NCT03758950)
- Testing
- Mometasone
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Jeffrey Glassberg
Hemoglobinopathies
Screening for Hemoglobinopathies in Pregnant Women
This prospective monocentric study project is to identify hemoglobinopathies in pregnant women in order to optimize antenatal care and to investigate the prevalence of hemoglobinopathies in pregnant women in Switzerland.
- Trial name
- NCT04029142
- Testing
- Review of routine lab data
- Where
- Switzerland
- Volunteers
- 1,785 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Sickle Cell Disease, Chronic Pain
Predictors of Pain in Sickle Cell Disease
Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling.
- Trial name
- NCT06139510
- Testing
- Quantitative sensory testing
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University
Anemia, Sickle Cell
Siplizumab for Sickle Cell Disease Transplant
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure.
- Trial name
- CD2 SCD (NCT06078696)
- Testing
- Siplizumab, Exchange Transfusion, Total Body Irradiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Sickle Cell Disease, Stroke
Stroke Prevention in Nigeria 2 Trial
The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA)…
- Trial name
- SPRING-2 (NCT06526117)
- Testing
- Hydroxyurea
- Where
- 2 sites in Nigeria
- Volunteers
- 220 people
- Sponsor
- Vanderbilt University Medical Center
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Sickle Cell Anemia
A Phase II Trial of Regadenoson in Sickle Cell Anemia
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a specific disease, in this case…
- Trial name
- NCT01788631
- Testing
- Regadenoson
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
HbS Disease, Hemoglobin S Disease
A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory.
- Conditions
- HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders
- Trial name
- NCT04201210
- Testing
- TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation
- Where
- 9 sites in Austria, Germany
- Volunteers
- 212 people
- Sponsor
- University of Regensburg
Sickle Cell Disease, Hemolytic Anemia
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.
- Trial name
- NCT07566494
- Testing
- VAS-101
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.